GLP-1 & Weight Management

The most well-known GLP-1 receptor agonist, approved for both diabetes and obesity. Backed by extensive clinical data and the largest user base of any weight loss medication.

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity. Demonstrates significant weight loss and metabolic improvements in large clinical trials.

A triple-agonist peptide (GIP/GLP-1/Glucagon receptor) showing the most dramatic weight loss results in clinical trials — up to 24% body weight reduction. Also showing anti-aging effects beyond weight loss.

FDA-approved weight management medication combining naltrexone (opioid antagonist) and bupropion (antidepressant). Targets the brain's reward system and appetite control center. An oral, non-GLP-1 option for weight management.

A long-acting amylin analog being studied in combination with semaglutide (CagriSema). Early results suggest enhanced weight loss beyond semaglutide alone.

Investigational oral GLP-1 receptor agonist by Eli Lilly. Unlike injectable GLP-1s, orforglipron is a small molecule taken as a daily pill. Phase 3 trials show significant weight loss and metabolic improvements comparable to injectable alternatives.

Investigational dual-action agonist targeting both GLP-1 and glucagon receptors by Boehringer Ingelheim. The glucagon component may enhance fat burning and energy expenditure beyond GLP-1-only drugs. Being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis).